Viiv Healthcare To Announce Data From Randomised Clinical Trial For 2-Drug Regimen Dovato Against 3-Drug Regimen Biktarvy At AIDs 2024
Viiv Healthcare To Announce Data From Randomised Clinical Trial For 2-Drug Regimen Dovato Against 3-Drug Regimen Biktarvy At AIDs 2024
维欣医疗公司将在艾滋病2024年会议上公布2种药物方案Dovato与3种药物方案Biktarvy的随机临床试验数据。
-
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato (dolutegravir/lamivudine) or Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- Additional key abstracts from ViiV Healthcare's industry-leading, long-acting pipeline and portfolio include data introducing a third-generation integrase strand transfer inhibitor (INSTI) with potential for ultra long-acting applications; pregnancy data for Apretude (cabotegravir long-acting injectable) for PrEP; and real-world evidence for long-acting treatment regimen Cabenuva (cabotegravir + rilpivirine long-acting)
- SEIMC-GeSIDA基金会(FSG)PASO-DOBLE研究的发现将包括参与者服用Dovato（多烯磷酸酯/拉米夫定）或Biktarvy（比克替格韦/恩替卡韦酯/阿拉芬酰胺）期间的治疗效果、安全性和体重增加。
- ViiV Healthcare领先行业的打破常规产品线和组合中，额外的重要摘要包括引入第三代整合酶链转移抑制剂(INSTI)，具有超长效应用潜力；Apretude(长效注射用卡博替格韦)在PrEP期间的孕妇数据；以及Cabenuva(卡博替格韦+利托猝灭韦长效)长效治疗方案的真实世界证据。